Floatz logo

Azacitidine

Acute

Molecular Partners AGSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Acute cohort.

Asset / SponsorPhaseRating
Paliperidone Palmitate 3-Month Formulation
Janssen Cilag N.V./S.A.
Phase 4BB
Vosaroxin
Sunesis Pharmaceuticals
Phase 2B
Tenecteplase
ProMedica Health System
Phase 2/3B
MP0533
Molecular Partners AG
Phase 1/2CCC
Venetoclax
Molecular Partners AG
Phase 1/2CCC

View all 9 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →
acute erythroid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →